Daiichi Sankyo Company, Limited today announced its 5-year Business Plan for fiscal 2021 – 2025.
The Daiichi Sankyo group of companies aspires to be an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society” The Daiichi Sankyo group of companies aims to address the social issues that we are expected by society to solve through our business activities, such as the creation of innovative pharmaceuticals and efforts for achieving the SDGs, and we will challenge ourselves to continuously provide innovative solutions based on our strength: Science & Technology.
Outline of the 5-year Business Plan
To achieve the 2030 vision, Daiichi Sankyo set the following four strategies as the pillars of the 5-year Business Plan, and identified the foundations to strengthen in order to support the execution of these strategies.
< Four strategic pillars >
Strategy 1: Maximize 3ADCs
Strategy 2: Profit growth for current business & products
Strategy 3: Identify and build pillars for further growth
Strategy 4: Create shared value with stakeholders
< Foundations to support strategy execution >
– Data-driven management through DX (digital transformation), and company-wide transformation
through advanced digital technology
– Agile decision making through new global management structure
Financial Targets in FY2025
To achieve the 2030 Vision, the following targets are set for fiscal 2025.
Revenue: 1.6 Trillion JPY
Oncology Revenue: 600.0 Billion JPY or more
Operating profit ratio before R&D expenses: 40 %
ROE: 16 % or more
Dividend on Equity: 18 % or more